Krystal Biotech, Inc. (NASDAQ:KRYS) Stock Position Raised by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D lifted its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 19.3% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 11,803 shares of the company’s stock after purchasing an additional 1,910 shares during the period. State of New Jersey Common Pension Fund D’s holdings in Krystal Biotech were worth $1,849,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of KRYS. State Street Corp raised its holdings in Krystal Biotech by 9.0% during the 3rd quarter. State Street Corp now owns 1,452,811 shares of the company’s stock worth $264,455,000 after buying an additional 119,936 shares during the period. Geode Capital Management LLC increased its position in shares of Krystal Biotech by 2.0% in the third quarter. Geode Capital Management LLC now owns 591,631 shares of the company’s stock worth $107,714,000 after acquiring an additional 11,411 shares in the last quarter. Franklin Resources Inc. raised its holdings in shares of Krystal Biotech by 34.2% during the third quarter. Franklin Resources Inc. now owns 243,760 shares of the company’s stock valued at $43,774,000 after acquiring an additional 62,178 shares during the period. Charles Schwab Investment Management Inc. lifted its position in shares of Krystal Biotech by 9.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 240,216 shares of the company’s stock valued at $43,727,000 after acquiring an additional 19,777 shares in the last quarter. Finally, Braidwell LP boosted its stake in Krystal Biotech by 57.4% in the 3rd quarter. Braidwell LP now owns 168,691 shares of the company’s stock worth $30,707,000 after purchasing an additional 61,512 shares during the period. 86.29% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Friday, December 13th. The shares were sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the transaction, the insider now directly owns 1,475,882 shares of the company’s stock, valued at $243,195,835.96. This represents a 1.67 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 14.10% of the stock is owned by company insiders.

Analyst Ratings Changes

KRYS has been the topic of several recent analyst reports. Chardan Capital boosted their target price on shares of Krystal Biotech from $212.00 to $218.00 and gave the company a “buy” rating in a research note on Thursday, February 20th. Citigroup upped their price target on Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a research report on Thursday, February 20th. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price objective on shares of Krystal Biotech in a research report on Thursday, February 20th. Finally, HC Wainwright reiterated a “buy” rating and issued a $221.00 target price on shares of Krystal Biotech in a report on Wednesday, February 19th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Krystal Biotech has an average rating of “Buy” and a consensus target price of $210.00.

Krystal Biotech Price Performance

Shares of Krystal Biotech stock opened at $181.10 on Wednesday. The firm has a market cap of $5.22 billion, a price-to-earnings ratio of 60.57 and a beta of 0.84. The stock has a 50-day simple moving average of $158.24 and a 200-day simple moving average of $175.31. Krystal Biotech, Inc. has a 52-week low of $125.85 and a 52-week high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, February 24th. The company reported $1.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.29 by $0.23. The firm had revenue of $91.10 million during the quarter, compared to analysts’ expectations of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The company’s revenue was up 116.4% compared to the same quarter last year. During the same period in the previous year, the company earned $0.30 earnings per share. As a group, equities research analysts predict that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).